Skip to main content

Table 2 Costs, health impacts and cost-effectiveness of rotavirus vaccines with comparison to no intervention

From: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Strategy Name Cost QALYs Incremental cost-effectiveness ratio ($/QALY)
No vaccine 7.524391 586.6089 −5.58
LLR vaccine 7.629827 586.0207 0
Rotarix vaccination 8.123035 1061.374 −2308.74
Rotateq vaccination 8.160051 975.9129 990.43
  1. Ratio of additional costs and benefits of a particular strategy compared with the no intervention strategy